Quantcast

Latest Amylin Stories

2011-04-27 15:15:00

SAN DIEGO, April 27, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Deutsche Bank 36th Annual Healthcare Conference on Wednesday, May 4, 2011 at 12:15 p.m. ET / 9:15 a.m. PT in Boston. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a...

2011-04-18 06:30:00

SAN DIEGO, April 18, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2011. The Company reported total revenue of $152.7 million for the quarter ended March 31, 2011, which includes net product sales of $150.8 million and revenues under collaborative agreements of $1.9 million. Non-GAAP operating loss was $3.2 million for the quarter ended March 31, 2011, compared to $3.8 million for the same period in 2010....

2011-04-11 15:15:00

SAN DIEGO, April 11, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the first quarter of 2011 on Monday, April 18, 2011 at 8:30 a.m. ET/5:30 a.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date pre-market, Amylin will release financial results for the first quarter of 2011. The call will be webcast live through the "Investors" section of Amylin's corporate...

2011-03-16 07:00:00

SAN DIEGO and OSAKA, Japan, March 16, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that they have suspended clinical activities in an ongoing Phase 2 study examining the safety and effectiveness of the investigational combination therapy pramlintide/metreleptin for the treatment of obesity. The clinical study was voluntarily halted to investigate a new antibody-related laboratory finding with...

2011-03-10 07:00:00

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced positive results from a phase 2 study evaluating the effects of a once-monthly injectable suspension formulation of exenatide on glycemic control in patients with type 2 diabetes. (Logo: https://photos.prnewswire.com/prnh/20101020/LA85062LOGO-a) (Logo:...

2011-03-09 15:15:00

SAN DIEGO, March 9, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Barclays Capital Global Healthcare Conference on Wednesday, March 16, 2011 at 10:45 a.m. ET / 7:45 a.m. PT in Miami. David Maggs, M.D., vice president, medical research and development at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording...

2011-03-03 07:00:00

SAN DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 3, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced top-line results from DURATION-6, a head-to-head study designed to compare weekly BYDUREON(TM) (exenatide extended-release for injectable suspension), an investigational type 2 diabetes therapy, to daily Victoza® (liraglutide (rDNA origin) injection). Both drugs are...

2011-02-08 15:15:00

SAN DIEGO, Feb. 8, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the ISI Annual Conference in New York on Tuesday, February 15, 2011 at 4:10 p.m. ET / 1:10 p.m. PT. Mark Foletta, senior vice president, finance and chief financial officer at Amylin Pharmaceuticals, will provide a corporate overview. The presentation will be webcast live through the "Investors" section of Amylin's corporate website at www.amylin.com, and the recording will be made...

2011-01-26 15:05:00

SAN DIEGO, Jan. 26, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2010. The Company reported total revenue of $174.2 million for the quarter ended December 31, 2010, including net product sales of $162.3 million and revenue under collaborative agreements of $11.9 million. Non-GAAP operating income was $22.9 million for the quarter ended December 31, 2010, compared to non-GAAP operating loss of...

2011-01-10 15:35:00

SAN FRANCISCO, Jan. 10, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today outlined its strategic corporate priorities for 2011, highlighting its continued focus on strong fiscal discipline while maximizing the value of the Company's diabetes franchise, notably through advancing the investigational compound BYDUREON(TM) (exenatide extended-release for injectable suspension) and other value-driving development programs. Daniel M. Bradbury, president and chief executive...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.